Simon Miles Ball
Directeur/Membre du Conseil chez Exelead, Inc.
Profil
Simon Miles Ball is currently a Director at Exelead, Inc., a Director at Leadiant Biosciences Ltd., the Global Head-Business Development at Leadiant Biosciences, Inc., and the Country General Manager at Leadiant Biosciences SpA.
He previously worked as a Non-Executive Director at Lee's Pharmaceutical Holdings Ltd.
from 2017 to 2021.
Mr. Ball received an undergraduate degree from the University of Leeds.
Postes actifs de Simon Miles Ball
| Sociétés | Poste | Début |
|---|---|---|
Exelead, Inc.
 Exelead, Inc. Pharmaceuticals: MajorHealth Technology Part of Merck KGaA, Exelead, Inc. is a biopharmaceutical contract development and manufacturing company. The company is based in Indianapolis, IN. John Rigg has been the CEO of the company since 2014. Exelead was acquired by Merck KGaA from Leadiant Biosciences SA on February 23, 2022 for $780 million. | Directeur/Membre du Conseil | - |
Leadiant Biosciences, Inc.
 Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Leadiant Biosciences, Inc. operates as a research-based pharmaceutical company. It develops and commercializes medicines for rare diseases. The company was founded in 1989 by Claudio Cavazza and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Leadiant Biosciences SpA
 Leadiant Biosciences SpA Pharmaceuticals: MajorHealth Technology Part of Valline Srl, Leadiant Biosciences SpA develops and manufactures pharmaceutical therapies for patients with rare diseases. The company is based in Rome, Italy. The Italian company was founded in 1957. Marco Maria Brughera has been the CEO of the company since 2011. Leadiant Biosciences was acquired by CHIESI Farmaceutici SpA on October 20, 2020. | Corporate Officer/Principal | - |
Leadiant Biosciences Ltd.
 Leadiant Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Leadiant Biosciences Ltd. researches, manufactures, and markets therapies for patients. The private company is based in London, UK, and has subsidiaries in Germany. The British company was founded in 1957. Antonio Gama da Silva has been the CEO of the company since 2016. | Directeur/Membre du Conseil | - |
Anciens postes connus de Simon Miles Ball
| Sociétés | Poste | Fin |
|---|---|---|
| LEE'S PHARMACEUTICAL HOLDINGS LIMITED | Directeur/Membre du Conseil | 30/06/2021 |
Formation de Simon Miles Ball
| University of Leeds | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LEE'S PHARMACEUTICAL HOLDINGS LIMITED | Health Technology |
| Entreprise privées | 4 |
|---|---|
Leadiant Biosciences, Inc.
Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Leadiant Biosciences, Inc. operates as a research-based pharmaceutical company. It develops and commercializes medicines for rare diseases. The company was founded in 1989 by Claudio Cavazza and is headquartered in Gaithersburg, MD. | Health Technology |
Exelead, Inc.
Exelead, Inc. Pharmaceuticals: MajorHealth Technology Part of Merck KGaA, Exelead, Inc. is a biopharmaceutical contract development and manufacturing company. The company is based in Indianapolis, IN. John Rigg has been the CEO of the company since 2014. Exelead was acquired by Merck KGaA from Leadiant Biosciences SA on February 23, 2022 for $780 million. | Health Technology |
Leadiant Biosciences SpA
Leadiant Biosciences SpA Pharmaceuticals: MajorHealth Technology Part of Valline Srl, Leadiant Biosciences SpA develops and manufactures pharmaceutical therapies for patients with rare diseases. The company is based in Rome, Italy. The Italian company was founded in 1957. Marco Maria Brughera has been the CEO of the company since 2011. Leadiant Biosciences was acquired by CHIESI Farmaceutici SpA on October 20, 2020. | Health Technology |
Leadiant Biosciences Ltd.
Leadiant Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Leadiant Biosciences Ltd. researches, manufactures, and markets therapies for patients. The private company is based in London, UK, and has subsidiaries in Germany. The British company was founded in 1957. Antonio Gama da Silva has been the CEO of the company since 2016. | Health Technology |